The Glycolytic Phenotype is Correlated with Aggressiveness and Poor Prognosis in Invasive Ductal Carcinomas

Overview

Journal J Breast Cancer

Date 2012 Jul 19

PMID 22807934

Citations 16

Authors

Se Min Jang

Hulin Han

Ki-Seok Jang

Young Jin Jun

Si-Hyong Jang

Kyueng-Whan Min

Min Sung Chung

Seung Sam Paik

Affiliations

Soon will be listed here.

Abstract

Purpose: Glucose uptake and glycolytic metabolism are enhanced in cancer cells, and increased expression of glucose transporter 1 (GLUT1) has also been reported. The aim of this study was to investigate GLUT1 expression in human breast tissues and invasive ductal carcinomas.

Methods: We used tissue microarrays consisting of normal breast tissue, ductal hyperplasia, ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastases. We examined GLUT1 expression in the microarrays by immunohistochemistry, reviewed the medical records and performed a clinicopathological analysis.

Results: Membranous GLUT1 expression was observed in normal and tumor cells. GLUT1 expression was higher in ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastasis than in normal tissue and ductal hyperplasia (p=0.002). Of 276 invasive ductal carcinomas, 106 (38.4%) showed GLUT1 expression. GLUT1 expression was correlated with higher histologic grade (p<0.001), larger tumor size (p=0.025), absence of estrogen receptor (p<0.001), absence of progesterone receptor (p<0.001), and triple-negative phenotype (p<0.001). In univariate survival analysis, patients with GLUT1 expression had poorer overall survival and disease-free survival (p=0.017 and p=0.021, respectively, log-rank test). In multivariate survival analysis with the Cox proportional hazards model, GLUT1 expression was an independent prognostic factor of poorer overall survival and disease-free survival (p=0.017 and p=0.019, respectively).

Conclusion: GLUT1 expression seems to play an important role in malignant transformation, and the glycolytic phenotype in invasive ductal carcinoma may indicate aggressive biological behavior and a worse prognosis.

Citing Articles

GLUT-1 may predict metastases and death in patients with locally advanced rectal cancer.

Kim T, Kwak Y, Song C, Lee H, Kim D, Oh H Front Oncol. 2023; 13:1094480.

PMID: 36968998 PMC: 10036037. DOI: 10.3389/fonc.2023.1094480.

Predicting response to neoadjuvant therapy with glucose transporter-1 in breast cancer.

Ozturk S, Ozturk C, Okcu O, Askan G, Sen B, Bedir R Rev Assoc Med Bras (1992). 2023; 69(3):440-446.

PMID: 36921199 PMC: 10004294. DOI: 10.1590/1806-9282.20221334.

Metabolic Phenotype Intricacies on Altered Glucose Metabolism of Breast Cancer Cells upon Glut-1 Inhibition and Mimic Hypoxia In Vitro.

Littleflower A, Antony G, Parambil S, Subhadradevi L Appl Biochem Biotechnol. 2023; 195(10):5838-5854.

PMID: 36708494 DOI: 10.1007/s12010-023-04373-5.

Pathological Significance of GLUT-1 Expression in Breast Cancer Cells in Diabetic and Obese Patients: The French Guiana Study.

Suteau V, Bukasa-Kakamba J, Virjogh-Cenciu B, Adenis A, Sabbah N, Alsibai K Cancers (Basel). 2022; 14(2).

PMID: 35053598 PMC: 8774256. DOI: 10.3390/cancers14020437.

Tumor stiffness measured by shear wave elastography correlates with tumor hypoxia as well as histologic biomarkers in breast cancer.

Yoo J, Seo B, Park E, Kwon M, Jeong H, Cho K Cancer Imaging. 2020; 20(1):85.

PMID: 33256820 PMC: 7706221. DOI: 10.1186/s40644-020-00362-7.

References

Brown R, Wahl R . Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer. 1993; 72(10):2979-85. DOI: 10.1002/1097-0142(19931115)72:10<2979::aid-cncr2820721020>3.0.co;2-x. View

Gatenby R, Gillies R . Why do cancers have high aerobic glycolysis?. Nat Rev Cancer. 2004; 4(11):891-9. DOI: 10.1038/nrc1478. View

Singletary S, Connolly J . Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin. 2006; 56(1):37-47. DOI: 10.3322/canjclin.56.1.37. View

Ravazoula P, Batistatou A, Aletra C, Ladopoulos J, Kourounis G, Tzigounis B . Immunohistochemical expression of glucose transporter Glut1 and cyclin D1 in breast carcinomas with negative lymph nodes. Eur J Gynaecol Oncol. 2003; 24(6):544-6. View

Ganapathy V, Thangaraju M, Prasad P . Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther. 2008; 121(1):29-40. DOI: 10.1016/j.pharmthera.2008.09.005. View

Carvalho K, Cunha I, Rocha R, Ayala F, Cajaiba M, Begnami M . GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics (Sao Paulo). 2011; 66(6):965-72. PMC: 3129958. DOI: 10.1590/s1807-59322011000600008. View

Kang S, Chun Y, Hur M, Lee H, Kim Y, Hong S . Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Jpn J Cancer Res. 2002; 93(10):1123-8. PMC: 5926879. DOI: 10.1111/j.1349-7006.2002.tb01214.x. View

Mellanen P, Minn H, Grenman R, Harkonen P . Expression of glucose transporters in head-and-neck tumors. Int J Cancer. 1994; 56(5):622-9. DOI: 10.1002/ijc.2910560503. View

Chen C, Chu J, Su W, Huang S, Lee W . Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX. Virchows Arch. 2010; 457(1):53-61. DOI: 10.1007/s00428-010-0938-0. View

10.

Hao L, Ni Q, Jia G, Wang G, Qian K, Liu Y . [Expression of glucose transporter 1 in human breast carcinoma and its clinical significance]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009; 40(1):44-7. View

11.

Semenza G . Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol. 2008; 19(1):12-6. DOI: 10.1016/j.semcancer.2008.11.009. View

12.

Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A . Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem. 2000; 276(12):9519-25. DOI: 10.1074/jbc.M010144200. View

13.

Sakashita M, Aoyama N, Minami R, Maekawa S, Kuroda K, Shirasaka D . Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinicopathological features. Eur J Cancer. 2001; 37(2):204-9. DOI: 10.1016/s0959-8049(00)00371-3. View

14.

Pinheiro C, Sousa B, Albergaria A, Paredes J, Dufloth R, Vieira D . GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. Histol Histopathol. 2011; 26(10):1279-86. DOI: 10.14670/HH-26.1279. View

15.

Hammond M, Hayes D, Dowsett M, Allred D, Hagerty K, Badve S . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010; 134(6):907-22. PMC: 3073033. DOI: 10.5858/134.6.907. View

16.

Younes M, Brown R, Mody D, Fernandez L, Laucirica R . GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res. 1995; 15(6B):2895-8. View

17.

Schmidt M, Voelker H, Kapp M, Krockenberger M, Dietl J, Kammerer U . Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and down-regulation of M2PK. J Cancer Res Clin Oncol. 2009; 136(2):219-25. DOI: 10.1007/s00432-009-0652-y. View

18.

Young C, Lewis A, Rudolph M, Ruehle M, Jackman M, Yun U . Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo. PLoS One. 2011; 6(8):e23205. PMC: 3149640. DOI: 10.1371/journal.pone.0023205. View

19.

Gordan J, Simon M . Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev. 2007; 17(1):71-7. PMC: 3215290. DOI: 10.1016/j.gde.2006.12.006. View

20.

Merrall N, Plevin R, Gould G . Growth factors, mitogens, oncogenes and the regulation of glucose transport. Cell Signal. 1993; 5(6):667-75. DOI: 10.1016/0898-6568(93)90028-k. View